- Merck announced a €50 million investment in its Bari production site.
- The new facility will be commissioned in 2017 for sterile filling and packaging.
- The Bari site is part of Merck Serono's global biotech production network.
- The investment aims to meet rising demand for biopharmaceuticals, especially infertility treatments.
Investment Announcement
Merck has announced a €50 million investment in its production site in Bari, Italy, to address the increasing demand for biopharmaceuticals. The announcement was made by Karl-Ludwig Kley, Chairman of the Executive Board of Merck, during a press conference at the Bari plant, attended by Italian Prime Minister Matteo Renzi and Farmindustria President Massimo Scaccabarozzi.
Production Expansion
The Bari site is part of Merck Serono’s global biotech production network, which includes facilities in Darmstadt and Aubonne, Switzerland. The new facility in Bari will be commissioned in 2017 and will focus on the sterile filling and packaging of liquid drugs into syringes, vials, and ampoules.
Strategic Importance
This investment is part of Merck's "Fit for 2018" transformation and growth program. The Bari site was chosen due to its highly skilled employees and excellent infrastructure. The expansion aims to secure the supply of drugs that improve the quality of life for patients worldwide.
Market Leadership
Merck generates over half of its Merck Serono division's sales from biotech products and is a global leader in infertility treatment. Approximately two million of the five million babies born with the help of infertility drugs worldwide were conceived using Merck Serono products.
